Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 354348, 7 pages
http://dx.doi.org/10.1155/2014/354348
Research Article

Characterization of Musclin as a New Target for Treatment of Hypertension

1Department of Neurosurgery, College of Medicine, Taipei Medical University and Shuang Ho Hospital, Taipei Medical University, Taipei City 10361, Taiwan
2Graduate Institute of Disease Prevention and Control, College of Medicine, Taipei Medical University and Shuang Ho Hospital, Taipei Medical University, Taipei City 10361, Taiwan
3Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan City 70101, Taiwan
4Department of Nursing, Tzu Chi College of Technology, Hualien City 97005, Taiwan

Received 11 January 2014; Accepted 1 February 2014; Published 9 March 2014

Academic Editor: Juei-Tang Cheng

Copyright © 2014 Jia-Wei Lin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Musclin is a novel skeletal muscle-derived factor found in the signal sequence trap of mouse skeletal muscle cDNAs. Recently, it has been demonstrated that musclin is involved in the pathogenesis of spontaneously hypertensive rats (SHRs). However, it is known as a genetic hypertension model. In the present study, we aim to investigate the role of musclin in another animal model of hypertension and characterize the direct effect of musclin on vascular contraction. The results show that expression of musclin was increased in arterial tissues isolated from DOCA-salt induced hypertensive rats or the normal rats received repeated vasoconstriction with phenylephrine. Additionally, direct incubation with phenylephrine did not modify the expression of musclin in the in vitro studies. Also, the direct effect of musclin on the increase of intracellular calcium was observed in a concentration-dependent manner. These results provide the evidence to support that musclin is involved in hypertension. Thus, musclin is suitable to be considered as a novel target for treatment of hypertension.